These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 10817522)
21. Endothelial survival factors as targets for antineoplastic therapy. Reinmuth N; Stoeltzing O; Liu W; Ahmad SA; Jung YD; Fan F; Parikh A; Ellis LM Cancer J; 2001; 7 Suppl 3():S109-19. PubMed ID: 11779081 [TBL] [Abstract][Full Text] [Related]
22. [Angiogenesis and antiangiogenic cancer therapy]. Pour L; Hájek R; Buchler T; Maisnar V; Smolej L Vnitr Lek; 2004 Dec; 50(12):930-8. PubMed ID: 15717808 [TBL] [Abstract][Full Text] [Related]
23. Colorectal cancer and antiangiogenic therapy: what can be expected in clinical practice? Mancuso A; Sternberg CN Crit Rev Oncol Hematol; 2005 Jul; 55(1):67-81. PubMed ID: 15890525 [TBL] [Abstract][Full Text] [Related]
24. Tumor angiogenesis--a potential target in cancer chemoprevention. Bhat TA; Singh RP Food Chem Toxicol; 2008 Apr; 46(4):1334-45. PubMed ID: 17919802 [TBL] [Abstract][Full Text] [Related]
25. Determination of angiogenesis in human neoplasms: current prognostic and therapeutic implications. Fontanini G; Del Mastro L; Bevilacqua G Forum (Genova); 1998; 8(2):128-42. PubMed ID: 9666050 [TBL] [Abstract][Full Text] [Related]
31. Molecular targets in the inhibition of angiogenesis. Dudek AZ; Pawlak WZ; Kirstein MN Expert Opin Ther Targets; 2003 Aug; 7(4):527-41. PubMed ID: 12885272 [TBL] [Abstract][Full Text] [Related]
32. Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications. Soultati A; Mountzios G; Avgerinou C; Papaxoinis G; Pectasides D; Dimopoulos MA; Papadimitriou C Cancer Treat Rev; 2012 Aug; 38(5):473-83. PubMed ID: 21982720 [TBL] [Abstract][Full Text] [Related]
33. Angiogenesis as a therapeutic target in cancer. Kumaran G; Clamp AR; Jayson GC Clin Med (Lond); 2008 Aug; 8(4):455-8. PubMed ID: 18724620 [No Abstract] [Full Text] [Related]
34. Antiangiogenic cancer drug using the zebrafish model. Santoro MM Arterioscler Thromb Vasc Biol; 2014 Sep; 34(9):1846-53. PubMed ID: 24903092 [TBL] [Abstract][Full Text] [Related]
36. A review on pro- and anti-angiogenic factors as targets of clinical intervention. Bouïs D; Kusumanto Y; Meijer C; Mulder NH; Hospers GA Pharmacol Res; 2006 Feb; 53(2):89-103. PubMed ID: 16321545 [TBL] [Abstract][Full Text] [Related]
37. Tumor angiogenesis--new drugs on the block. Brower V Nat Biotechnol; 1999 Oct; 17(10):963-8. PubMed ID: 10504695 [No Abstract] [Full Text] [Related]
38. An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action. Gradishar WJ Invest New Drugs; 1997; 15(1):49-59. PubMed ID: 9195289 [TBL] [Abstract][Full Text] [Related]
39. Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Silletti S; Kessler T; Goldberg J; Boger DL; Cheresh DA Proc Natl Acad Sci U S A; 2001 Jan; 98(1):119-24. PubMed ID: 11134507 [TBL] [Abstract][Full Text] [Related]
40. Mechanisms and future directions for angiogenesis-based cancer therapies. Scappaticci FA J Clin Oncol; 2002 Sep; 20(18):3906-27. PubMed ID: 12228212 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]